Combined α-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7–positive prostate cancer cells

Kassi, 2011, Glucocorticoid receptor signaling and prostate cancer, Cancer Lett, 302, 1, 10.1016/j.canlet.2010.10.020 Watson, 2015, Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer, Nat Rev Cancer, 15, 701, 10.1038/nrc4016 Graham, 2016, Targeting persistent androgen receptor signaling in castration-resistant prostate cancer, Med Oncol, 33, 44, 10.1007/s12032-016-0759-3 Vlachostergios, 2017, Emerging Variants of Castration-Resistant Prostate Cancer, Curr Oncol Rep, 19, 32, 10.1007/s11912-017-0593-6 Hornberg, 2011, Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival, PLoS One, 6, 10.1371/journal.pone.0019059 Hu, 2012, Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer, Cancer Res, 72, 3457, 10.1158/0008-5472.CAN-11-3892 Ferdinandusse, 2000, Subcellular localization and physiological role of alpha-methylacyl-CoA racemase, J Lipid Res, 41, 1890, 10.1016/S0022-2275(20)31983-0 Suh, 2005, Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma, Mod Pathol, 18, 1217, 10.1038/modpathol.3800407 Ha, 2010, Alpha-methylacyl-coenzyme a racemase-expressing urachal adenocarcinoma of the abdominal wall, Korean J Urol, 51, 498, 10.4111/kju.2010.51.7.498 Xu, 2000, Identification of differentially expressed genes in human prostate cancer using subtraction and microarray, Cancer Res, 60, 1677 Attard, 2016, Prostate cancer, Lancet, 387, 70, 10.1016/S0140-6736(14)61947-4 Petrylak, 2004, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, 1513, 10.1056/NEJMoa041318 Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Brooke, 2009, The role of androgen receptor mutations in prostate cancer progression, Curr Genomics, 10, 18, 10.2174/138920209787581307 Ho, 2017, Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer, Endocrinology, 158, 1533, 10.1210/en.2017-00109 Henzler, 2016, Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer, Nat Commun, 7, 13668, 10.1038/ncomms13668 Zha, 2003, Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer, Cancer Res, 63, 7365 Takahara, 2009, Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression, Anticancer Res, 29, 2497 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Galletti, 2017, Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer, Cancer Treat Rev, 57, 16, 10.1016/j.ctrv.2017.04.008 Higano, 2011, New and emerging agents for the treatment of castration-resistant prostate cancer, Urol Oncol, 29, S1, 10.1016/j.urolonc.2011.08.013 Paller, 2011, Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer, Drug Des Devel Ther, 5, 117 Hongo, 2018, Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer, Cancer Sci, 109, 2937, 10.1111/cas.13729 Kiliccioglu, 2019, Hsp-27 and NF-kappaB pathway is associated with AR/AR-V7 expression in prostate cancer cells, Gene, 697, 138, 10.1016/j.gene.2019.02.055 Rocchi, 2004, Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer, Cancer Res, 64, 6595, 10.1158/0008-5472.CAN-03-3998